AGENTS FOR IMPROVING INFLAMMATORY BOWEL DISEASE

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20090202517A1
SERIAL NO

11576040

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present inventors discovered for the first time that intestinal inflammation could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, inflammation in the large intestine can be suppressed by using siRNA to suppress the expression of versican, which is one of the chondroitin sulfate proteoglycans. Compounds used as siRNA, such as nucleic acids, can be used as effective agents for suppressing intestinal inflammation. Furthermore, the above finding also suggests that such intestinal inflammation-suppressing agents can be found by screening for compounds that suppress the production or accumulation of chondroitin sulfate proteoglycans.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
STELIC INSTITUTE OF REGENERATIVE MEDICINE STELIC INSTITUTE & COTOKYO 106-0044

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Wakamatsu, Kyoko Tokyo , JP 1 2
Yoneyama, Hiroyuki Tokyo , JP 177 1018

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation